Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

Prostate

Volumn 42, Issue 4, 2000, Pages 274-279

  Ahlgren, Göran ^a,d   Pedersen, K ^b   Lundberg, S ^b   Aus, G ^c   Hugosson, J ^c   Abrahamsson, P A ^a  

^a LUND UNIVERSITY   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Neoadjuvant treatment; Neuroendocrine differentiation; Prostate cancer; PSA; Radical prostatectomy

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER HORMONE THERAPY; CANCER REGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; CHROMOGRANIN A; CHROMOGRANINS; GONADOTROPIN-RELEASING HORMONE; HUMANS; KI-67 ANTIGEN; MALE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0033962683     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R     Document Type: Article

References (18)

1. Garnick MB, Glode LM, for the Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281-1286.
2. Aus G. Prostate cancer. Mortality and morbidity after noncurative treatment with aspects on diagnosis and treatment. Medical dissertation, Göteborg. Scand J Urol Nephrol [Suppl] 1994.
3. Grönberg H, Bergh A, Damber J-E, Jonsson H, Lenner P, Ångström T. Prostate cancer in northern Sweden. Incidence, survival and mortality in relation to tumour grade. Acta Oncol 1994;33:359-363.
4. di Sant'Agnese AP. Neuroendocrine differentiation in prostatic carcinoma. Cancer [Suppl] 1995;75:1850-1859.
5. Abrahamsson PA, Falkmer S, Fält K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. Pathol Res Pract 1989;185:373-380.
6. Jiborn T, Bjartell A, Abrahamsson P-A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589.
7. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
8. Deftos LJ, Nakada S, Burton DW, di Sant'Angese PA, Cockett AT, Abrahamsson P-A. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
9. Nakada SY, di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett ATK, Abrahamsson P-A. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967-1970.
10. Hugosson J, Abrahamsson P-A, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment. Eur Urol 1996;29:413-419.
11. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology [Suppl] 1997;49:16-22.
12. Cattoretti G, Becker MHG, Key G, Duchrov M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (Mib1 and Mib 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
13. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic carcinoma. Cancer 1993;71:3952-3965.
14. Soloway M, Sharif R, Wajsman Z, McLeod D, Wood D, Puras-Baez A, for the Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy preceeded by androgen blockade in clinical stage B2 (T2b) prostate cancer. J Urol 1995;154:424-428.
15. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospctiven randomized trial. J Urol 1995;154:429-434.
16. Van de Voorde WM, Elgamal AA, Van Poppel HP, Verbeken EK, Baert LV, Lauweryns JM. Morphologic and immunahistochemical changes in prostate cancer after preoperative hormonal therapy. Cancer 1994;74:3164-3175.
17. McLeod DG, Johnson CF, Klein E, Peabody JO, Coffield S, Soloway M, Lupron Depot Neoadjuvant Study Group. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens proceeded by androgen blockade in clinical B2 (T2bNxM0) prostate cancer. Urology [Suppl] 1997;49:70-73.
18. Krijnen JLM, Bogdanowicz JFAT, Seldenrijk CA, Mulder PGH, Van der Kvast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158: 171-174.